Market Research Logo

Mallinckrodt LLC - Product Pipeline Analysis, 2018 Update

Summary

Mallinckrodt LLC (Mallinckrodt), formerly Therakos Inc, a subsidiary of Mallinckrodt Plc, is a provider of autologous immune cell therapy through extracorporeal photopheresis. The company provides Therakos Cellex Photopheresis system, which is indicated for use in ultraviolet-A irradiation in the presence of the photoactive drug 8-methoxypsoralen. It’s treatment offers relief from the skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients not responding to other forms of treatment. Mallinckrodt also provides innovative treatment platforms that harness the patients' immune systems to fight diseases such as cystic fibrosis, graft versus host disease, and peripheral T-cell lymphoma. The company serves academic medical centers, hospitals, and treatment centers in the US. Mallinckrodt is headquartered in St. Louis, Missouri, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Mallinckrodt LLC
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Mallinckrodt LLC Company Overview
Mallinckrodt LLC Company Snapshot
Mallinckrodt LLC Pipeline Products and Ongoing Clinical Trials Overview
Mallinckrodt LLC – Pipeline Analysis Overview
Mallinckrodt LLC - Key Facts
Mallinckrodt LLC - Major Products and Services
Mallinckrodt LLC Pipeline Products by Development Stage
Mallinckrodt LLC Ongoing Clinical Trials by Trial Status
Mallinckrodt LLC Pipeline Products Overview
CELLEX System - Crohn's Disease
CELLEX System - Crohn's Disease Product Overview
CELLEX System - Graft Versus Host Disease
CELLEX System - Graft Versus Host Disease Product Overview
EpiReady
EpiReady Product Overview
ExpressGraft - Antineoplastic
ExpressGraft - Antineoplastic Product Overview
ExpressGraft C9T1 Skin Tissue
ExpressGraft C9T1 Skin Tissue Product Overview
ExpressGraft C9T1 Skin Tissue Clinical Trial
ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers
ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers Product Overview
ExpressGraft Pro-Angiogenic - Venous Leg Ulcers
ExpressGraft Pro-Angiogenic - Venous Leg Ulcers Product Overview
Mallinckrodt LLC - Key Competitors
Mallinckrodt LLC - Key Employees
Mallinckrodt LLC - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mallinckrodt LLC, Recent Developments
Mar 20, 2018: Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation
Feb 27, 2018: TGA Safety Alert On Therakos Cellex Photopheresis System
Feb 19, 2018: New VaxArray Potency Test Kit for Pandemic Flu Vaccines
Feb 14, 2018: Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue
Sep 05, 2017: Mallinckrodt Statement on Praxair Patent Infringement Ruling
May 03, 2017: Mallinckrodt Celebrates 30th Anniversary of THERAKOS Photopheresis Therapy
Oct 20, 2016: Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in Five U.S States
Sep 23, 2016: Validity of Mallinckrodt's INOMAX Patent Claims Upheld
Sep 23, 2016: Validity of Mallinckrodt's INOMAX Patent Claims Upheld
Aug 23, 2016: Extracorporeal Photopheresis, Including Mallinckrodt's THERAKOS ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Mallinckrodt LLC Pipeline Products and Ongoing Clinical Trials Overview
Mallinckrodt LLC Pipeline Products by Equipment Type
Mallinckrodt LLC Pipeline Products by Indication
Mallinckrodt LLC Ongoing Clinical Trials by Trial Status
Mallinckrodt LLC, Key Facts
Mallinckrodt LLC, Major Products and Services
Mallinckrodt LLC Number of Pipeline Products by Development Stage
Mallinckrodt LLC Pipeline Products Summary by Development Stage
Mallinckrodt LLC Ongoing Clinical Trials by Trial Status
Mallinckrodt LLC Ongoing Clinical Trials Summary
CELLEX System - Crohn's Disease - Product Status
CELLEX System - Crohn's Disease - Product Description
CELLEX System - Graft Versus Host Disease - Product Status
CELLEX System - Graft Versus Host Disease - Product Description
EpiReady - Product Status
EpiReady - Product Description
ExpressGraft - Antineoplastic - Product Status
ExpressGraft - Antineoplastic - Product Description
ExpressGraft C9T1 Skin Tissue - Product Status
ExpressGraft C9T1 Skin Tissue - Product Description
ExpressGraft C9T1 Skin Tissue - An Open-label, Prospective, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers - Product Status
ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers - Product Description
ExpressGraft Pro-Angiogenic - Venous Leg Ulcers - Product Status
ExpressGraft Pro-Angiogenic - Venous Leg Ulcers - Product Description
Mallinckrodt LLC, Key Employees
Mallinckrodt LLC, Other Locations
Mallinckrodt LLC, Subsidiaries
Glossary
List of Figures
Mallinckrodt LLC Pipeline Products by Equipment Type
Mallinckrodt LLC Pipeline Products by Development Stage
Mallinckrodt LLC Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report